Skip to Content

American Cryostem Corp CRYO Stock Quote

| Rating as of


Market Closed

| Currency in USD

  • Last Close < 0.01
  • Sector Healthcare
  • Industry Biotechnology
  • Investment Style
  • Day Range < 0.01  –  < 0.01
  • Year Range < 0.01  –  0.39
  • Market Cap 53,135.1348
  • Volume / Avg 200.0 /  3,420.6
  • Price / Sales
  • Price / Book
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis CRYO

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics CRYO

Company Profile CRYO

Business Description

American Cryostem Corp is a biotechnology company which standardizes adipose tissue-derived technologies (Adult Stem Cells) for the fields of Regenerative and Personalized Medicine. The company acts as an innovator of adipose tissue and stem cell platform technologies. It provides the clinical grade, adipose tissue and adult stem cell collection, processing, and cryo-preservation technology, providing first-in-class cellular therapy products and services for patients, physicians and researchers based on the transformative science of Regenerative and Personalized Medicine.

1 Meridian Road, Suite 5
Eatontown, NJ, 07724
Industry Biotechnology
Employees 6

Our Quantitative Research team models direct competitors or comparable companies from a bottom-up perspective to find companies describing their business in a similar fashion.

American Cryostem Corp


Molecular Templates Inc


Pulse Biosciences Inc


Nykode Therapeutics AS Ordinary Shares

$0.00 (9.09%) +$0.06 (0.92%) +$0.08 (1.94%) +$0.10 (0.36%)
Market Cap
53,135.1335.52 Mil230.59 Mil8.27 Bil
Biotechnology Biotechnology Medical Instruments & Supplies Biotechnology

* Trading data in this section is delayed by at least 15 minutes.

FAQs for American Cryostem Corp Stock

No. CRYO does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

CRYO’s market cap is 53,135.13.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

CRYO’s stock style is Small Core.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

CRYO’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare CRYO’s historical performance against its industry peers and the overall market.